Lexicon Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public, Subsidiary

Established: 1995-01-01

Employees: 285

Market Cap: $621.7M

Website: http://www.lexpharma.com

Introduction: Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company...

Clinical Trials

Study to Determine the Absorption, Metabolism, and Excretion of [14C]LX4211 in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: [14C]-LX4211

First Posted Date: 2013-03-26

Last Posted Date: 2013-06-18

Lead Sponsor: Lexicon Pharmaceuticals

Target Recruit Count: 8

Registration Number: NCT01818232

Locations: 🇺🇸
Lexicon Investigational Site, Madison, Wisconsin, United States

Safety and Efficacy of Sotagliflozin (LX4211) in Patients With Inadequately Controlled Type 1 Diabetes Mellitus

Phase 2

Completed

Conditions: Type 1 Diabetes Mellitus

Interventions: Drug: Sotagliflozin
Drug: Placebo

First Posted Date: 2012-12-05

Last Posted Date: 2020-02-12

Lead Sponsor: Lexicon Pharmaceuticals

Target Recruit Count: 36

Registration Number: NCT01742208

Locations: 🇺🇸
Lexicon Investigational Site, Dallas, Texas, United States

TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)

Phase 3

Completed

Conditions: Carcinoid Syndrome

Interventions: Drug: Telotristat etiprate
Drug: Placebo-matching telotristat etiprate

First Posted Date: 2012-09-03

Last Posted Date: 2018-02-27

Lead Sponsor: Lexicon Pharmaceuticals

Target Recruit Count: 135

Registration Number: NCT01677910

Locations: 🇮🇱
Lexicon Invetigational Site, Jerusalem, Israel
🇬🇧
Lexicon Investigational Site, Newcastle upon Tyne, United Kingdom

Study to Evaluate the Pharmacodynamic and Pharmacokinetic Effects of LX4211 in Subjects With Type 2 Diabetes and Renal Impairment

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus
Renal Impairment

Interventions: Drug: LX4211
Drug: LX4211 Placebo

First Posted Date: 2012-03-15

Last Posted Date: 2013-09-09

Lead Sponsor: Lexicon Pharmaceuticals

Target Recruit Count: 31

Registration Number: NCT01555008

Locations: 🇺🇸
Lexicon Investigational Site, Renton, Washington, United States

Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

Phase 1

Completed

Conditions: Primary Open-angle Glaucoma
Ocular Hypertension

Interventions: Drug: LX7101 Vehicle
Drug: LX7101 (0.125%)
Drug: LX7101 (0.25%)

First Posted Date: 2012-02-07

Last Posted Date: 2015-09-14

Lead Sponsor: Lexicon Pharmaceuticals

Target Recruit Count: 63

Registration Number: NCT01528111

Locations: 🇺🇸
Lexicon Investigational Site, San Antonio, Texas, United States

A Multi-Center Trial to Determine the Safety and Efficacy of LX1033 in Subjects With Diarrhea-Predominant Irritable Bowel Syndrome

Phase 2

Completed

Conditions: Irritable Bowel Syndrome

Interventions: Drug: 250 mg LX1033 tablets
Drug: Placebo tablet

First Posted Date: 2011-12-16

Last Posted Date: 2015-03-23

Lead Sponsor: Lexicon Pharmaceuticals

Target Recruit Count: 373

Registration Number: NCT01494233

Locations: 🇺🇸
Lexicon Investigational Site, Virginia Beach, Virginia, United States

A Study to Evaluate Safety and Efficacy of Telotristat Etiprate (LX1606) in Participants With Acute, Mild to Moderate Ulcerative Colitis

Phase 2

Completed

Conditions: Ulcerative Colitis

Interventions: Drug: Telotristat Etiprate
Drug: Placebo

First Posted Date: 2011-10-20

Last Posted Date: 2019-05-23

Lead Sponsor: Lexicon Pharmaceuticals

Target Recruit Count: 59

Registration Number: NCT01456052

Locations: 🇸🇰
Lexicon Investigational Site, Nove Mesto nad Vahom, Slovakia

A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 Diabetics

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: LX4211
Drug: Januvia®

First Posted Date: 2011-09-27

Last Posted Date: 2012-01-31

Lead Sponsor: Lexicon Pharmaceuticals

Target Recruit Count: 18

Registration Number: NCT01441232

Locations: 🇺🇸
Lexicon Investigational Site, San Antonio, Texas, United States

A Study to Determine the Safety and Efficacy of LX3305 in Subjects With Active Rheumatoid Arthritis

Phase 1

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: 50 mg LX3305 QD
Drug: 100 mg LX3305 QD
Drug: 150 mg LX3305 QD
Drug: 200 mg LX3305 QD
Drug: 250 mg LX3305 QD
Drug: 300 mg LX3305 QD
Drug: 400 mg LX3305 QD
Drug: 250 mg LX3305 BID
Drug: 500 mg LX3305 QD
Drug: Placebo

First Posted Date: 2011-08-16

Last Posted Date: 2012-08-02

Lead Sponsor: Lexicon Pharmaceuticals

Target Recruit Count: 10

Registration Number: NCT01417052

Locations: 🇺🇸
Lexicon Investigational Site, Dallas, Texas, United States

An Open-Label Study of Two Formulations of LX1033 in Healthy Human Subjects

Phase 1

Completed

Conditions: Irritable Bowel Syndrome

Interventions: Drug: 250 mg capsule
Drug: 250 mg tablets

First Posted Date: 2011-08-08

Last Posted Date: 2012-07-20

Lead Sponsor: Lexicon Pharmaceuticals

Target Recruit Count: 28

Registration Number: NCT01411800

Locations: 🇺🇸
Lexicon Investigational Site, Overland Park, Kansas, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy